CLS vs MSFT

Celestica Inc. exhibits a stark divergence between its explosive growth metrics and its deterministic health indicators, highlighted by a weak Piotroski F-Score of 3/9. While the company delivers exceptional revenue (43.6%) and earnings (77.7%) growth with a consistent track record of beats, the current price of $410.21 represents a massive premium over both the Graham Number ($55.82) and the growth-based Intrinsic Value ($211.81). The combination of bearish insider selling and a weak technical trend suggests the stock may be overextended despite strong analyst sentiment. Consequently, the valuation risk currently outweighs the growth momentum.

Microsoft exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust financial stability. While the stock is currently experiencing a severe technical downtrend (0/100) and significant 6-month price depreciation (-28.6%), the current price of $374.33 sits well below the growth-based intrinsic value of $471.41 and the analyst target of $587.31. Exceptional earnings growth (59.8% YoY) and high operating margins (47.09%) suggest that the current price correction presents a value opportunity despite bearish insider sentiment.